Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$45.48 USD
-0.06 (-0.13%)
Updated May 22, 2024 04:00 PM ET
After-Market: $45.50 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 101 - 120 ( 184 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:13 Financial Results and Update- Higher-Than- Anticipated Loss on Higher R&D Spend - Eyes On EU Launches - Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G